Cargando…

Payer perceptions of the use of real-world evidence in oncology-based decision making

BACKGROUND: Randomized controlled trials (RCTs), the gold standard of safety and efficacy evidence, are conducted in select patients that may not mirror real-world populations. As a result, healthcare decision makers may have limited information when making formulary decisions, especially in oncolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brixner, Diana, Biskupiak, Joseph, Oderda, Gary, Burgoyne, Douglas, Malone, Daniel C, Arondekar, Bhakti, Niyazov, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390932/ https://www.ncbi.nlm.nih.gov/pubmed/34337998 http://dx.doi.org/10.18553/jmcp.2021.27.8.1096

Ejemplares similares

Payer perceptions on the use of economic models in oncology decision making
por: Biskupiak, Joseph, et al.
Publicado: (2021)

Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making
por: Brixner, Diana I., et al.
Publicado: (2012)

Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions
por: Roberts, Melissa H., et al.
Publicado: (2020)

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
por: Mistry, Rohit, et al.
Publicado: (2018)

BRCA1/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel
por: Mahtani, Reshma, et al.
Publicado: (2022)

Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
por: Arondekar, Bhakti, et al.
Publicado: (2022)

Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer in the United States, Europe, and Israel
por: Mahtani, Reshma, et al.
Publicado: (2022)

RE: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
por: Zou, Denise, et al.
Publicado: (2021)

Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel
por: Mahtani, Reshma, et al.
Publicado: (2022)

Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients
por: Saverno, Kim R., et al.
Publicado: (2012)

Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel
por: Mahtani, Reshma, et al.
Publicado: (2022)

Real-world evidence enhances decision making
por: Malone, Daniel C
Publicado: (2020)

Cost Implications of Formulary Decisions on Oral Anticoagulants in Nonvalvular Atrial Fibrillation
por: Biskupiak, Joseph, et al.
Publicado: (2013)

Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians
por: Yang, Jingyan, et al.
Publicado: (2021)

Introduction
por: Brixner, Diana I., et al.
Publicado: (2012)

“This Drug May Work, But Is It Worth the Cost?” Can Comparative Effectiveness Research Help Tame Rising Health Care Costs?
por: Brixner, Diana I., et al.
Publicado: (2012)

Standardizing Quality Assessment of Observational Studies for Decision Making in Health Care
por: Brixner, Diana
Publicado: (2009)

Using Certification to Promote Uptake of Real-World Evidence by Payers
por: Segal, Jodi B., et al.
Publicado: (2016)

Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study
por: Nadler, Eric, et al.
Publicado: (2020)

Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis
por: Rochau, Ursula, et al.
Publicado: (2015)

Removing anonymity protection and utilization review decisions: a real-world case under a single-payer health system
por: Wang, Chih-Kuang, et al.
Publicado: (2022)

Smog, Cognition and Real-World Decision-Making
por: Chen, Xi
Publicado: (2018)

Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making
por: Berger, Marc L., et al.
Publicado: (2017)

The impact of race on survival in metastatic prostate cancer: a systematic literature review
por: Freedland, Stephen J., et al.
Publicado: (2023)

Pharmacoepidemiology Research-Real-World Evidence for Decision Making
por: Bérard, Anick
Publicado: (2021)

Real-world use and perceptions of shared decision-making for allergy and asthma care in a US population
por: Eghrari-Sabet, Jacqueline, et al.
Publicado: (2023)

Barriers to and Facilitators of Evidence-Based Decision Making at the Point of Care: Implications for Delivery Systems, Payers, and Policy Makers
por: O’Malley, Ann S., et al.
Publicado: (2016)

Real world data: Additional source for making clinical decisions
por: Mahajan, Rajiv
Publicado: (2015)

Improving patient-reported measures in oncology: a payer call to action
por: Schmidt, Theresa, et al.
Publicado: (2021)

Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative
por: Edgar, Babette S, et al.
Publicado: (2021)

Real-world evidence for regulatory decision-making: updated guidance from around the world
por: Burns, Leah, et al.
Publicado: (2023)

All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial Fibrillation
por: Ghate, Sameer R., et al.
Publicado: (2011)

Payer perceptions and use of value assessment tools in the United States
por: Westrich, Kimberly, et al.
Publicado: (2023)

Real-world data mining : applied business analytics and decision making
por: Delen, Dursun
Publicado: (2014)

Facilitating shared decision-making in oncology
por: Sobrero, Alberto, et al.
Publicado: (2023)

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
por: Solà-Morales, Oriol, et al.
Publicado: (2019)

Making the Case for Addressing Health Disparities: What Drives Providers and Payers?
por: Johnson, Margaret, et al.
Publicado: (2018)

Trends in outpatient emergency department visits during the COVID-19 pandemic at a large, urban, academic hospital system
por: Giannouchos, Theodoros V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pudrrt7k4qsl5nnaiga8hrb4aj